Omeros Corporation (0KBU.L)

3,0880 -0,1220 (-3,80%) In data: 06:55PM BST. Mercato aperto.

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 198

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Gregory A. Demopulos M.D.	Co-Founder, Chairman, CEO & President	1,79M	N/D	1959
Mr. Michael A. Jacobsen	Chief Accounting Officer, VP of Finance & Treasurer	518,6k	N/D	1958
Mr. Peter B. Cancelmo J.D.	VP, General Counsel & Corporate Secretary	503,24k	N/D	1979
Dr. Pamela Pierce Palmer M.D., Ph.D.	Co-Founder	N/D	N/D	1963
Dr. George A. Gaitanaris M.D., Ph.D.	Chief Scientific Officer & VP of Science	N/D	N/D	1957
Mr. Peter W. Williams	Vice President of Human Resources	N/D	N/D	1968
Dr. Catherine A. Melfi Ph.D.	Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems	N/D	N/D	1959
Ms. Nadia Dac	VP & Chief Commercial Officer	N/D	N/D	1970
Dr. Andreas Grauer M.D.	VP & Chief Medical Officer	N/D	N/D	1961

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Omeros Corporation al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 5; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.